XNYS · Medical Devices
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$205.04-1.44%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
46/100
Moderate
Score components
TickerWhale View
Steris scores 46 out of 100 overall, which we rate moderate. Valuation is its strongest area and Technical its weakest.
What helps
- Valuation
- Risk
What to watch
- Technical
- Quality & growth
Quality & growth
30%34Weak
- Revenue growth 8.4%
- EPS growth 25.3%
Valuation
25%70Positive
- P/E 24.9
- EV/Sales 3.6
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.
#463 by market cap in our coverage · ~17,937 employees · Listed 1992-06-02 · www.steris.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#108 / 139sector rank by TickerWhale Score
TickerWhale Score 46 vs sector average 55.1 (-9.1)
Revenue growth (industry)Top 72%
Gross margin (industry)Top 94%
Return on equity (industry)Top 39%
P/E (industry)Cheaper than 67%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
27/100Weak vs universe
Ranks 27th of 100 covered names on our technical composite — the composite itself scores 35/100 · 25% of the TickerWhale Score
Classic chart indicators
Sell
3 buy · 5 sell · 0 neutral of 8 votes
TickerWhale rates STE's technical setup weak — 27th percentile of the covered universe. Classic chart indicators lean sell, pointing the same way.
Moving averages
0 / 9constructive
- vs 200-day-11.1%
- vs 50-day-8.8%
Momentum
Constructive
- RSI (14)25 · buy
- Stochasticbuy
- CCIsell
- Williams %Rbuy
Trend
Weak
- ADX (14) trend strength29· trending
- MACD (12,26,9)sell(histogram -2.310)
How the classic verdict is reached
Moving averages (9) agree on sell — 0 buy vs 9 sell — and carry one vote between them.
Oscillators (7) vote individually: 3 buy · 4 sell · 0 neutral.
Result — 3 buy vs 5 sell of 8 votes = Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)24.9
- P/S (TTM)3.3
- P/B2.8
- EV/EBITDA—
- EV/Sales3.6
- PEG0.99
Profitability & returns
- Gross margin44.4%
- Net margin13.3%
- ROE11.2%
- Debt/Equity0.26
Growth
- Revenue growth (YoY)8.4%
- EPS growth (YoY)25.3%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $20.1B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| STECurrentSteris | 46 | 35 | 24.9 | — | 2.8 | 3.6 | $205.04 | -1.44% | +8.4% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.